b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30817250</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>03</Month>\n            <Day>31</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>05</Month>\n            <Day>01</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1527-7755</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>37</Volume>\n                    <Issue>13</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>05</Month>\n                        <Day>01</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>\n                <ISOAbbreviation>J. Clin. Oncol.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1062-1069</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.18.01295</ELocationID>\n            <Abstract>\n                <AbstractText Label="PURPOSE">Pegylated recombinant human hyaluronidase (PEGPH20) degrades hyaluronan (HA) and, in combination with chemotherapy, prolongs survival in preclinical models. The activity of PEGPH20 with modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) was evaluated in patients with metastatic pancreatic cancer (mPC).</AbstractText>\n                <AbstractText Label="MATERIALS AND METHODS">Patients had untreated mPC, a performance status of 0 to 1, and adequate organ function. Tumor HA status was not required for eligibility. After a phase Ib dose-finding study of mFOLFIRINOX plus PEGPH20, the phase II open-label study randomly assigned patients (1:1) to the combination arm or to mFOLFIRINOX alone (n = 138). The primary end point was overall survival (OS).</AbstractText>\n                <AbstractText Label="RESULTS">PEGPH20 dosages of 3 \xc2\xb5g/kg every 2 weeks were more tolerable than twice-weekly dosages used in the phase I study, so 3 \xc2\xb5g/kg every 2 weeks was the phase II dosage. An amendment instituted enoxaparin prophylaxis in the PEGPH20 combination arm as a result of increased thromboembolic (TE) events. The planned interim futility analysis when 35 deaths (of 103 analyzable patients) occurred resulted in an OS hazard ratio (HR) of 2.07 that favored the control arm, and the study was closed to accrual. The treatment-related grade 3 to 4 toxicity was significantly increased in the PEGPH20 combination arm relative to control (odds ratio, 2.7; 95% CI, 1.1 to 7.1). The median OS in the mFOLFIRINOX arm was 14.4 months (95% CI, 10.1 to 15.7 months) versus 7.7 months (95% CI, 4.6 to 9.3 months) in the PEGPH20 combination arm.</AbstractText>\n                <AbstractText Label="CONCLUSION">Addition of PEGPH20 to mFOLFIRINOX seems to be detrimental in patients unselected for tumor HA status. This combination caused increased toxicity (mostly GI and TE events) and resulted in decreased treatment duration compared with mFOLFIRINOX alone. The median OS in the mFOLFIRINOX control arm (14.4 months) is, to our knowledge, the longest yet reported and can be considered for patients with good PS.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Ramanathan</LastName>\n                    <ForeName>Ramesh K</ForeName>\n                    <Initials>RK</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>1 Mayo Clinic Cancer Center, Phoenix, AZ.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>McDonough</LastName>\n                    <ForeName>Shannon L</ForeName>\n                    <Initials>SL</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>2 Southwest Oncology Group Statistics and Data Management Center, Seattle, WA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>3 Fred Hutchinson Cancer Research Center, Seattle, WA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Philip</LastName>\n                    <ForeName>Philip A</ForeName>\n                    <Initials>PA</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>4 Karmanos Cancer Institute/Wayne State University, Detroit, MI.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hingorani</LastName>\n                    <ForeName>Sunil R</ForeName>\n                    <Initials>SR</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>3 Fred Hutchinson Cancer Research Center, Seattle, WA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lacy</LastName>\n                    <ForeName>Jill</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>5 Yale Cancer Center, New Haven, CT.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kortmansky</LastName>\n                    <ForeName>Jeremy S</ForeName>\n                    <Initials>JS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>5 Yale Cancer Center, New Haven, CT.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Thumar</LastName>\n                    <ForeName>Jaykumar</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>5 Yale Cancer Center, New Haven, CT.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>6 Saint Francis Hospital and Medical Center, Enfield, MA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Chiorean</LastName>\n                    <ForeName>E Gabriela</ForeName>\n                    <Initials>EG</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>3 Fred Hutchinson Cancer Research Center, Seattle, WA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>7 University of Washington, Seattle, WA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Shields</LastName>\n                    <ForeName>Anthony F</ForeName>\n                    <Initials>AF</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>4 Karmanos Cancer Institute/Wayne State University, Detroit, MI.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Behl</LastName>\n                    <ForeName>Deepti</ForeName>\n                    <Initials>D</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>8 Sutter Cancer Research Consortium, Sacramento, CA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Mehan</LastName>\n                    <ForeName>Paul T</ForeName>\n                    <Initials>PT</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>9 Heartland NCI Community Oncology Research Program (NCORP), Missouri Baptist Medical Center Cancer Center, St Louis, MO.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Gaur</LastName>\n                    <ForeName>Rakesh</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>10 Kansas City NCI Community Oncology Research Program (NCORP), Prairie Village, KS.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Seery</LastName>\n                    <ForeName>Tara</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>11 UC Irvine Medical Center, Orange, CA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Guthrie</LastName>\n                    <ForeName>Katherine A</ForeName>\n                    <Initials>KA</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>2 Southwest Oncology Group Statistics and Data Management Center, Seattle, WA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>3 Fred Hutchinson Cancer Research Center, Seattle, WA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hochster</LastName>\n                    <ForeName>Howard S</ForeName>\n                    <Initials>HS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>12 Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <DataBankList CompleteYN="Y">\n                <DataBank>\n                    <DataBankName>ClinicalTrials.gov</DataBankName>\n                    <AccessionNumberList>\n                        <AccessionNumber>NCT01959139</AccessionNumber>\n                    </AccessionNumberList>\n                </DataBank>\n            </DataBankList>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>U10 CA180826</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>UG1 CA189830</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>U10 CA180828</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>UG1 CA189853</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>UG1 CA233163</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>U10 CA046368</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>U10 CA180888</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>U10 CA180830</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>UL1 TR001863</GrantID>\n                    <Acronym>TR</Acronym>\n                    <Agency>NCATS NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>N01 CA013612</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>U10 CA013612</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>U10 CA180835</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>UG1 CA189848</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>U10 CA180846</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>UG1 CA180830</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>UG1 CA189858</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>U10 CA180819</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>UG1 CA189953</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>UG1 CA233328</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>\n                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>\n                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>02</Month>\n                <Day>28</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>J Clin Oncol</MedlineTA>\n            <NlmUniqueID>8309333</NlmUniqueID>\n            <ISSNLinking>0732-183X</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C000627770">folfirinox</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>04ZR38536J</RegistryNumber>\n                <NameOfSubstance UI="D000077150">Oxaliplatin</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>7673326042</RegistryNumber>\n                <NameOfSubstance UI="D000077146">Irinotecan</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>9004-61-9</RegistryNumber>\n                <NameOfSubstance UI="D006820">Hyaluronic Acid</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 3.2.1.35</RegistryNumber>\n                <NameOfSubstance UI="D006821">Hyaluronoglucosaminidase</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 3.2.1.35</RegistryNumber>\n                <NameOfSubstance UI="C000632509">PEGPH20</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>Q573I9DVLP</RegistryNumber>\n                <NameOfSubstance UI="D002955">Leucovorin</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>U3P01618RT</RegistryNumber>\n                <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <CommentsCorrectionsList>\n            <CommentsCorrections RefType="CommentIn">\n                <RefSource>J Clin Oncol. 2019 May 1;37(13):1041-1043</RefSource>\n                <PMID Version="1">30860950</PMID>\n            </CommentsCorrections>\n        </CommentsCorrectionsList>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>\n                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006820" MajorTopicYN="N">Hyaluronic Acid</DescriptorName>\n                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006821" MajorTopicYN="N">Hyaluronoglucosaminidase</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000077146" MajorTopicYN="N">Irinotecan</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002955" MajorTopicYN="N">Leucovorin</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000077150" MajorTopicYN="N">Oxaliplatin</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>\n                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>3</Month>\n                <Day>1</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>4</Month>\n                <Day>1</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>3</Month>\n                <Day>1</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30817250</ArticleId>\n            <ArticleId IdType="doi">10.1200/JCO.18.01295</ArticleId>\n            <ArticleId IdType="pmc">PMC6494359</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Eur J Cancer. 2009 Jan;45(2):228-47</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19097774</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Expert Rev Anticancer Ther. 2018 Feb;18(2):131-148</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29254387</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Br J Cancer. 2018 Jan;118(2):153-161</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28949957</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Cell. 2012 Mar 20;21(3):418-29</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22439937</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2018 Feb 1;36(4):359-366</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29232172</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Pancreas. 2013 Nov;42(8):1311-5</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24152956</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Gut. 2013 Jan;62(1):112-20</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22466618</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Cancer Res. 2016 Jun 15;22(12):2848-54</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26813359</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Cancer Res. 2018 May 15;24(10):2241-2250</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29269376</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2016 Aug 10;34(23):2784-96</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27247222</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2011 May 12;364(19):1817-25</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21561347</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Gastroenterology. 2018 Mar;154(4):820-838</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29287624</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Colorectal Cancer. 2018 Sep;17(3):187-197</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29615310</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Curr Oncol Rep. 2017 Jul;19(7):47</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28589527</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Chemother Pharmacol. 2018 Jun;81(6):1017-1023</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29633005</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Br J Cancer. 2016 Sep 6;115(6):649-54</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27467054</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Biometrics. 1975 Mar;31(1):103-15</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">1100130</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Mol Cancer Ther. 2010 Nov;9(11):3052-64</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20978165</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2015 Oct 1;33(28):3199-212</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26169616</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Chin Clin Oncol. 2017 Dec;6(6):65</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29307204</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2013 Oct 31;369(18):1691-703</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24131140</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Cancer Res. 2015 Aug 1;21(15):3561-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25695692</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2015 Dec 20;33(36):4284-92</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26527777</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'